ライフサイエンスコーパス: contrast agent

1 he same injectate (2 mL corticosteroid, 3 mL contrast agent).

2 ed and fat-suppressed T2-weighted images (no contrast agent).

3 images acquired with or without the use of a contrast agent.

4 uction of free radicals without an exogenous contrast agent.

5 Fe-PyC3A, as a biochemically responsive MRI contrast agent.

6 e-guided therapy with clinical-grade SonoVue contrast agent.

7 f liver tumors and were able to receive a CT contrast agent.

8 proportional to the concentration of iodine contrast agent.

9 anges were not significantly associated with contrast agent.

10 K-1, in addition to serving as an ultrasound contrast agent.

11 technique by employing a stimuli-responsive contrast agent.

12 ol has gained considerable interest as an MR contrast agent.

13 ength and administration of gadolinium-based contrast agent.

14 e level without the need for any staining or contrast agent.

15 ensitivity of a hyperpolarized xenon-129 MRI contrast agent.

16 ing agent, and a PDA shell, acting as the PA contrast agent.

17 nsity varies with different gadolinium-based contrast agents.

18 adverse effects induced by gadolinium-based contrast agents.

19 s after exposure to various gadolinium-based contrast agents.

20 explored as magnetic resonance imaging (MRI) contrast agents.

21 as effective diamagnetic CEST (diaCEST) MRI contrast agents.

22 he imaged tissue and the injected PA-imaging contrast agents.

23 on of multiple materials including iodinated contrast agents.

24 real-time and without the need for exogenous contrast agents.

25 red (NIR) fluorophores into red-shifted SWIR contrast agents.

26 r by the design of responsive or activatable contrast agents.

27 of time-domain USF imaging by using two USF contrast agents.

28 in the path to human translation of optical contrast agents.

29 serve as an alternative to gadolinium-based contrast agents.

30 gn paradigm for biochemically responsive MRI contrast agents.

31 nitude higher than those of gadolinium-based contrast agents.

32 ts the translational potential of MPIO-based contrast agents.

33 duce cavitation of lipid-shelled microbubble contrast agents.

34 linical and research use of gadolinium-based contrast agents.

35 ich can be potentially employed as inhalable contrast agents.

36 t compete with Gd(III) complexes as T(1) MRI contrast agents.

37 le administrations of linear and macrocyclic contrast agents.

38 cal properties for this class of bright SWIR contrast agents.

39 regional volume without introduction of any contrast agents.

40 at microscale resolutions without exogenous contrast agents.

41 ding the photophysics of common optoacoustic contrast agents.

42 h varying concentrations of gadolinium-based contrast agent (0, 0.4, 0.8, 1.2, 1.6, and 2 mmol/mL) an

43 with NSF, all MRI examinations performed and contrast agents administered to these patients were reco

44 to eliminate the need for a speculum during contrast agent administration and image capture.

45 re the relationship between gadolinium-based contrast agent administration and irregularities by comp

46 Gadolinium-based contrast agent administration changed according to recen

47 = 4263) or without (n = 16 111) intravenous contrast agent administration for a variety of unrelated

48 To compare intravenous versus intra-arterial contrast agent administration in relationship to AKI and

49 There were no adverse events related to contrast agent administration.

50 ffers between intravenous and intra-arterial contrast agent administration.

51 The results showed that the USF contrast agent adopted in this study was very stable in

52 photothermal (and potentially photoacoustic) contrast agent, allowing for photothermal imaging of the

53 tients receive an oral dose of a fluorescent contrast agent and a fibre-optic probe is used to make f

54 and HIFU are limited by the half-life of the contrast agent and challenges in accurate control of lar

55 r, owing to non-specific accumulation of the contrast agent and its efflux from the cells, most of th

56 concentration, pO(2), and Pi using a single contrast agent and Overhauser-enhanced magnetic resonanc

57 shell) nanoparticles (GTNPs@PANI) as an OCT contrast agent and pH-responsive nanoprobe for 3D imagin

58 s, participants received an infusion of a US contrast agent and saline.

59 for its visualization are invasive, require contrast agents and demonstrate collateral vessels, rath

60 s, technological advances such as ultrasound contrast agents and elastography, and above all increase

61 uable tool for in vitro fertilization, where contrast agents and fluorophores may impact the viabilit

62 hieved USF imaging with several types of USF contrast agents and imaging systems.

63 or requesting the study, CT findings, use of contrast agents and reasons for using them, and, in pati

64 e advantages and limitations of current T(1) contrast agents and the potential of IONPs to serve as s

65 Here, recent progress of PA contrast agents and their biomedical applications are ou

66 ure research and investigation of PA-imaging contrast agents and their significance in biomedical res

67 sing passive cavitation detection (PCD), MRI-contrast agents and, importantly, also by sensitive fluo

68 very in real time using a nanoparticle-based contrast agent, and glioma-specific targeting significan

69 The effects of patient age, sex, contrast agent, and manual region-of-interest versus ful

70 ystem, the descending aorta was flushed with contrast agent, and OCT images were obtained with a pull

71 aterally perfused with an iodinated vascular contrast agent, and three extracted formalin-fixed spina

72 typically low concentrations of fluorescent contrast agents, and tissue motion.

73 al ions; as nonlinear optical materials, MRI contrasting agents, and sensitizers for photodynamic the

74 PA contrast agents are classified according to their compon

75 right, photostable, and nontoxic fluorescent contrast agents are critical for biological imaging.

76 In recent years, a series of PA-imaging contrast agents are developed to improve the PA-imaging

77 Here, the fundamental principles of MRI contrast agents are discussed, and the current status of

78 ymer nanoparticles, and nonlinear PA-imaging contrast agents are discussed.

79 igh-performance and clinically relevant T(1) contrast agents are discussed.

80 Gadolinium (Gd)-based contrast agents are extensively used for magnetic resona

81 Background US contrast agents are gas-filled microbubbles (MBs) that c

82 Gadolinium-based contrast agents are implicated in several pathologic abn

83 photodynamic therapy, exogenous photothermal contrast agents are not required for photothermal therap

84 The applications of PA contrast agents as biosensors (in the sensing of metal i

85 tecting and quantifying one paramagnetic MRI contrast agent at a time.

86 nclusion At 3.0 T, use of a gadolinium-based contrast agent at follow-up MRI did not change the diagn

87 sporter mediated aggregation of biotinylated contrast agent (b-BSA-Gd-DTPA).

88 n approach for developing superbright NIR-II contrast agents based on the synergy between chemical sy

89 n-weighted sequence, and a multiecho dynamic contrast agent-based sequence.

90 nd laceration and bleeding with extraluminal contrast agent blush of the arterial main trunk 7%.

91 eudoaneurysm 57%, bleeding with extraluminal contrast agent blush of the terminal arterial segment 36

92 Gadodiamide (linear contrast agent) but not gadoterate meglumine (macrocycli

93 T include high radiation exposure and iodine contrast agent, but its effectiveness in reducing mortal

94 mitation by improving the conspicuity of the contrast agent, but more data are needed.

95 toxic contrast material, or gadolinium-based contrast agent.(C) RSNA, 2020.

96 We show that the fluorescent contrast agent can be used to quantify the expression le

97 Although molecularly targeted optical contrast agents can be used to define tumour margins dur

98 hat sub-micron sized 'nanobubble' ultrasound contrast agents can be used to measure increased islet m

99 Smart/intelligent contrast agent candidates for MRI based on Mn(II) ion ar

100 nthesis of a new class of nanoparticle-based contrast agents comprising self-assembled NaGdF(4) and C

101 the magnetic resonance signal intensity and contrast agent concentration. Furthermore, respiratory m

102 show that an intravenously administered MRI contrast agent consisting of a paramagnetic polymer coat

103 R imaging with a clinically approved optical contrast agent could serve as a useful adjunct in assess

104 of the spray mechanism demonstrates that the contrast agent delivery enables satisfactory administrat

105 view of recent successes in gadolinium-based contrast agent development and assess the requirements f

106 positioning is maintained, and the magnetic contrast agent diffuses out of the hydrogel, supporting

107 development of a completely new class of MRI contrast agents, displaying remarkable relaxation effect

108 of DR in patients that received <=100 ml of contrast agent (DR n = 26: Deltacreatinine -0.03(-0.20,0

109 rhythms showed the lowest redistribution of contrast agent during the light phase or time of inactiv

110 can be imaged through the use of fluorescent contrast agents during surgical procedures to complement

111 etric cardiac and respiratory motion phases, contrast-agent dynamics, and blood flow velocity fields.

112 d high-absorbance near-infrared optoacoustic contrast agent, E4(x12)-Cy7.

113 Next we describe efforts to make safer contrast agents either by increasing relaxivity, increas

114 ull-field digital (FFD) mammography, dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) im

115 dial sparse parallel (GRASP)-derived dynamic contrast agent-enhanced (DCE) MRI with established diffu

116 Background Dynamic contrast agent-enhanced (DCE) perfusion MRI may help dif

117 oxygenation by using dynamic susceptibility contrast agent-enhanced (DSC) MRI and evaluate its poten

118 t high risk for breast cancer undergo annual contrast agent-enhanced breast MRI screening examination

119 noncontrast (VNC) images from a single-phase contrast agent-enhanced examination, potentially reducin

120 s, including participants with at least five contrast agent-enhanced examinations and normal kidney f

121 rpose To evaluate the clinical usefulness of contrast agent-enhanced interstitial transpedal MR lymph

122 retrospective study, patients who underwent contrast agent-enhanced late venous phase spectral CT of

123 Conclusion This study indicated that dynamic contrast agent-enhanced perfusion MRI parameter, fractio

124 Gross spinal cord anatomy, spinal meninges, contrast agent-enhanced spinal vasculature, and spinal n

125 Large contrast agent-enhanced tumors were shown in mice with g

126 intensity projection images to emphasize the contrast agent-enhanced vasculature.

127 f sestamibi SPECT/CT and 4D CT (noncontrast, contrast agent-enhanced, arterial, and delayed venous ph

128 (CNN) to radiologists for classification of contrast agent-enhancing lesions as benign or malignant

129 ollow the redistribution of intraventricular contrast agent entrained to the light-dark cycle and its

130 ever received injections of gadolinium-based contrast agent) examined with a standard T1-weighted two

131 rted, only seven were after gadolinium-based contrast agent exposure after 2008, indicating that regu

132 function (groups 3 and 4) without history of contrast agent exposure were included for comparison.

133 erms of safety, effectiveness, radiation and contrast agent exposure.

134 es (AuNPs) have been applied as a multimodal contrast agent for both OCT and PAM imaging by taking ad

135 ese data show that ss-CyFaP is an accessible contrast agent for deep tissue PAI in the NIR-II window.

136 as an E944 food additive) as a new inhalable contrast agent for diagnostic detection via MRI.

137 Iron oxide nanoparticles are an alternative contrast agent for MRI.

138 PEG-AuNPs offer an efficient and safe contrast agent for multimodal ocular imaging to achieve

139 nanoparticles (TSPNs) are investigated as a contrast agent for photoacoustic (PA) imaging in the sec

140 PDA NP as an efficient NIR-II/PAI dual-modal contrast agent for precision medicine.

141 h as DDAO arachidonate may serve as a useful contrast agent for the visualization of tumor margins in

142 ophane host molecules provide ultrasensitive contrast agents for (129)Xe NMR/MRI.

143 l and other sugar alcohol derivatives as MRI contrast agents for a variety of preclinical imaging app

144 on of inhalable or injectable hyperpolarized contrast agents for biomedical imaging.

145 lasmonic nanoparticles are explored as image contrast agents for both superlocalization and super-res

146 ere have recently been many reports of novel contrast agents for CT imaging.

147 utilised as magnetic resonance imaging (MRI) contrast agents for decades.

148 ollege of Radiology group 2 gadolinium-based contrast agents for hypersensitivity reactions and nephr

149 -wave infrared (SWIR) emission are promising contrast agents for in vivo animal imaging, providing hi

150 ce or the use of hyperpolarized particles as contrast agents for in vivo imaging.

151 Gadolinium-based chelates are a mainstay of contrast agents for magnetic resonance imaging (MRI) in

152 offer great potential for the development of contrast agents for magnetic resonance imaging (MRI).

153 oparticles, which are developed primarily as contrast agents for magnetic resonance imaging, limits t

154 uture design of drug delivery nanosystems or contrast agents for neurovascular pathologies.

155 oses (<0.5 mg kg(-1)), emerging as unrivaled contrast agents for NIR-II preclinical bioimaging.

156 /- 1.5 nm) were demonstrated to be excellent contrast agents for PAM and OCT, and do not demonstrate

157 hese DHCA functionalized IONPs are promising contrast agents for stem cell tracking by T2-weighted MR

158 nts in animals through the design of optical contrast agents for the shortwave infrared (SWIR, 1,000-

159 with microvascularization, elastography, and contrast agents for use in children, have increased the

160 Histological iron imaging and contrast-agent free magnetic resonance imaging (MRI) can

161 rates that high-frequency UMI is a low-cost, contrast-agent-free, easily applicable, accessible, and

162 ent challenges in developing IONPs as a T(1) contrast agent from a materials science perspective are

163 sess the effect of spiropyran positioning on contrast agent functions and properties.

164 The contrast agent gadobutrol (0.2mmol/kg [0.2ml/kg]) was ad

165 e-2,2-indoline], which is linked with an MRI contrast agent, gadolinium-1,4,7,10-tetraazacyclododecan

166 ministration (FDA)-approved gadolinium-based contrast agent, gadopentetate dimeglumine (Gd(DTPA)(2-))

167 tudies with the macrocyclic gadolinium-based contrast agent gadoterate meglumine.

168 nistration of two different gadolinium-based contrast agents, gadoxetate and gadoterate, at free-brea

169 BackgroundThe safety of gadolinium-based contrast agent (GBCA) exposure during pregnancy has not

170 identified higher rates of gadolinium-based contrast agent (GBCA) exposure during the first few week

171 um retention after repeated gadolinium-based contrast agent (GBCA) exposure has been reported in subc

172 ities following intravenous gadolinium-based contrast agent (GBCA) exposure might be related to blood

173 jections of the macrocyclic gadolinium-based contrast agent (GBCA) gadoterate meglumine on the signal

174 MRF T(1) measurements post gadolinium-based contrast agent (GBCA) injection and the utility of such

175 ersensitivity reaction to a gadolinium-based contrast agent (GBCA) often had breakthrough reactions.

176 of Radiology as a group III gadolinium-based contrast agent (GBCA), which indicates that there are li

177 d more sensitively detected gadolinium-based contrast agent (GBCA).

178 Gadolinium-based contrast agents (GBCAs) are frequently used in patients

179 contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast

180 Gadolinium-based contrast agents (GBCAs) are used to provide diagnostic i

181 und Despite the wide use of gadolinium-based contrast agents (GBCAs) for enhanced MRI, their neuroche

182 following administration of gadolinium-based contrast agents (GBCAs) for MRI examinations.

183 iple administrations of the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and

184 Gadolinium based contrast agents (GBCAs) have been linked to toxicity in

185 oresponsive Gd(III)-based magnetic resonance contrast agents (GBCAs) in 1997.

186 is (NSF) affects the use of gadolinium-based contrast agents (GBCAs) in MRI, there continues to be li

187 trathecal administration of gadolinium-based contrast agents (GBCAs) is limited by a lack of understa

188 l injections of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal intensity (SI) of

189 osure to newer versus older gadolinium-based contrast agents (GBCAs) remains unclear.

190 persensitivity reactions to gadolinium-based contrast agents (GBCAs) that occur despite corticosteroi

191 t of hepatobiliary-specific gadolinium-based contrast agents (GBCAs) within the liver and kidneys usi

192 er administration of linear gadolinium-based contrast agents (GBCAs), in line with persistent brain g

193 in high cumulative doses of gadolinium-based contrast agents (GBCAs).

194 multiple administrations of gadolinium-based contrast agents (GBCAs).

195 c events between classes of gadolinium-based contrast agents (GBCAs).

196 th prior exposure to linear gadolinium-based contrast agents (GBCAs).

197 atients undergoing MRI with gadolinium-based contrast agents (GBCAs).

198 t Ktrans describing extravasation of the MRI contrast agent Gd-DTPA was significantly increased in bo

199 g the intra-tumoral concentration of two MRI contrast agents (Gd-BOPTA and Dy-DOTA-azide) in a mouse

200 Injectable Magnetic Resonance Imaging (MRI) contrast agents have been widely used to provide critica

201 Studies in developing IONPs as T(1) contrast agents have generated promising results, but th

202 s regulations of the use of gadolinium-based contrast agents have required that the indications for t

203 These contrast agents have shown great promise for visualizing

204 r hypoxia studies using an intrinsic optical contrast agent (hemoglobin), up to cm depth and 0.1-mm s

205 Imaging was conducted at 1 and 2 h post contrast agent immersion.

206 Gadolinium-based contrast agents improved diagnostic performance in detec

207 the concentration of a gadolinium-containing contrast agent in a region of interest, thereby allowing

208 ate, we explore its ability to function as a contrast agent in fluorescence-guided surgery.

209 ss-sectional CT allows for direct viewing of contrast agent in the VES, providing improved spread ass

210 because of the lack of stable near-infrared contrast agents in a biological environment and the lack

211 Synchronous assessment of multiple MRI contrast agents in a single scanning session would provi

212 The development of high-performance contrast agents in magnetic resonance imaging (MRI) has

213 However, the large size of the few available contrast agents in this spectral range impedes their pha

214 ed erythrocyte-derived transducers (NETs), a contrast agent, in combination with a photoacoustic imag

215 s potential characteristics for targeted MRI contrast agents, including high relaxivity, unappreciabl

216 Contrast agent injection was well tolerated without comp

217 an 9 minutes examination time, works without contrast agent injection, and offers a diagnostic accura

218 -wrap artifacts can be reduced by moving the contrast agent intravenous line out of the FOV during ac

219 the target cells with a nontoxic and stable contrast agent is a prerequisite.

220 xcellent temporal resolution, the dual-modal contrast agent is capable for high sensitivity real-time

221 -responsive magnetic resonance imaging (MRI) contrast agent is presented.

222 velopment of gold nanoparticles (AuNP) as CT contrast agents is a topic of intense interest.

223 Though the blood elimination half-life of contrast agents is about 90 minutes, recent studies demo

224 nt of sensitive and chemically selective MRI contrast agents is imperative for the early detection an

225 surgery in real time, the selectivity of the contrast agents is often limited by the target being exp

226 Nevertheless, using extrinsic contrast agents is often too invasive for routine clinic

227 deoff between intrinsic imaging and external contrast agents is particularly acute in reproductive me

228 are discussed, and the current status of MRI contrast agents is reviewed with a focus on the advantag

229 In the pursuit of novel MRI contrast agents, it is hoped that this review will spur

230 ements that surround it without the need for contrast agents; its ability to evaluate the elasticity

231 nning was done, which allowed measurement of contrast agent kinetics with high temporal resolution.

232 In addition, the USPIO contrast agent labeled macrophages were shown to be pres

233 o date, the scope of responsive (129) Xe NMR contrast agents lacks breadth in the specific detection

234 t) but not gadoterate meglumine (macrocyclic contrast agent) led to pain hypersensitivity, but neithe

235 ualization relative to the commercially used contrast agent Magnevist.

236 e synthesized a manganese-based paramagnetic contrast agent, ManICS1-AM, designed to permeate cells,

237 The electric-field-responsive contrast agent may increase the probability of detecting

238 Herein, we employ MLS to analyze contrast agents (methylene blue, rhodamine 800, Alexa Fl

239 ombined with systemic infusion of ultrasound contrast agent microbubbles (MB) causes localized blood-

240 Finally we survey approaches to make contrast agents more specific for pathology either by di

241 ngths (1, 1.5, 3, and 7 T) and the effect of contrast agent on DNA double-strand-break (DSB) formatio

242 col via the use of iodinated and gadolinated contrast agents on four healthy New Zealand White (NZW)

243 n sensitivity.Keywords: Efficacy Studies, MR-Contrast Agent, Oncology, Soft Tissues/Skin(C) RSNA, 202

244 n a push to develop new molecularly targeted contrast agents or agents that can sense pathological ch

245 ith a folate receptor targeted near-infrared contrast agent (OTL38) can improve malignant pulmonary n

246 rared fluorescently-labeled, tumor-targeting contrast agent, panitumumab-IRDye800CW, to facilitate th

247 This heterogeneous redistribution of contrast agent paralleled the gradients and regional var

248 bicin (Dox) were co-loaded with a nanobubble contrast agent (perfluoropentane, PFP) using a one-step

249 romise due to its low cost and fast speed of contrast agent preparation.

250 rt a collagen type I targeting protein-based contrast agent (ProCA32.collagen1) with strong collagen

251 Thus, sub-micron sized nanobubble ultrasound contrast agents provide a predicative marker for disease

252 SPCCT is able to distinguish between two contrast agents referred to as multicolor imaging becaus

253 iated with seizures trigger breakdown of the contrast agent, restoring the T1-weighted magnetic reson

254 Administration of intravenous contrast agent resulted in negligible differences in mea

255 l lanthanide complexes relavant to PARASHIFT contrast agents reveals unexpected trends in the magneti

256 cles were excluded if they focused solely on contrast agents, served as commentaries/overviews on NIR

257 The microdroplets served as carriers for PA contrast agent solution in the innermost part while oil

258 Callascope contains a 2 megapixel camera and contrast agent spray mechanism housed within a form fact

259 Background Previous studies analyzed contrast agent spread during cervical interlaminar epidu

260 o assess associations between covariates and contrast agent spread to particular locations.

261 An MRI-based contrast agent such as ADx-001 is attractive because of

262 kes it ideal for tumor-dose enhancement with contrast agents such as iodine or gold nanoparticles, an

263 t significant advancements in ultrasound and contrast agent technology have paved the way for therape

264 ) N(3) ]nimorazole as a theragnostic hypoxia contrast agent that can be potentially deployed in the n

265 n of a rotaxane-based (129) Xe hyperCEST NMR contrast agent that can be turned on in response to H(2)

266 circulating blood-pool liposomal gadolinium contrast agent that does not penetrate the placental bar

267 An optical molecular imaging contrast agent that is tailored toward lymphatic mapping

268 often requires the addition of an exogenous contrast agent that may have limited tissue access.

269 n part, by the lack of bright, biocompatible contrast agents that absorb and emit light above 1000 nm

270 on of quantitative dynamic MRI scanning with contrast agents that are sensitive to the reduction in b

271 he tissue structure but lacks specificity to contrast agents that could be used for in vivo molecular

272 Microbubble contrast agents that undergo ultrasound-mediated cavitat

273 the state of the art of clinically approved contrast agents, their mechanism of action, and factors

274 ed to a corresponding time-varying iodinated contrast agent to create the contrast material-enhanced

275 to standardize surgical navigation tools and contrast agents to facilitate swift regulatory approval.

276 of focal liver lesions and uses microbubble contrast agents to increase signal backscattering from t

277 sed to deliver small molecule cargos such as contrast agents to permit future in vivo tracking of Epi

278 Purpose To develop and validate a robust, contrast agent-unenhanced, free-breathing three-dimensio

279 m(2) [59-171 Grayxcm(2)]; P=0.06), and lower contrast agent use (200 mL [150-310 mL] versus 250 mL [2

280 Conventional responsive contrast agents used in (1) H MRI are impaired by the hi

281 Gadolinium contrast agents used in MRI are distributed within the t

282 ntrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic.

283 Magnetic resonance imaging (MRI) aided by contrast agents utilizes the differential relaxivity pro

284 agents at different times so that the first contrast agent visualized the portal phase and the secon

285 Extravasation of the contrast agent was defined as anastomotic leakage.

286 Global brain redistribution of contrast agent was heterogeneous.

287 rast swallow with the use of a water-soluble contrast agent was performed on the 5(th) postoperative

288 ction of 1.5 ml/kg of body mass of non-ionic contrast agent was performed.

289 measured at 0.55 T; relaxivity of exogenous contrast agents was measured; and clinical applications

290 laxation rate after administration of an MRI contrast agent, was significantly higher in the sonicate

291 ter-based optical coherence tomography (OCT) contrast agent, we have greatly extended OCT imaging dep

292 Patients who drank the oral contrast agent were taken to a 64-detector row multiple

293 Gadolinium-based contrast agents were not approved in the United States f

294 A series of light-activatable MRI contrast agents were synthesized and characterized to as

295 ocrystalline iron-oxide nanoparticles (MION) contrast agent, which has a more temporally extended res

296 The contrast agents, which improve diagnostic accuracy, are

297 The primary results indicated that the contrast agent with a five-carbon linker (25) showed the

298 By dynamically modulating signals from the contrast agents with an external near-infrared optical s

299 se as an acoustically activatable ultrasound contrast agent, with the hypothesis that incorporation o

300 Using a contrast agent, zirconium-substituted Keggin polyoxometa